Biotech StocksStock News Company Update (NYSE MKT:RNN): NCI Accepts Rexahn Pharmaceuticals, Inc.’s RX-21101 for Its Preclinical Characterization Program Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that its drug candidate … Corey Williams, June 8, 2015
Biotech StocksStock News Company Update (NYSE MKT:RNN): Rexahn Pharmaceuticals, Inc. Reports First Quarter 2015 Financial Results and Pipeline Update Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an update of its three … Corey Williams, May 11, 2015
Biotech StocksStock News Company Update (NYSE MKT:RNN): New Data Show Rexahn Pharmaceuticals Inc’s Supinoxin(TM) Decreases Migration of Human Triple Negative Breast Cancer Cells in Metastatic Cancer Model Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that it presented preclinical … Corey Williams, April 21, 2015
Biotech StocksStock News Stock Update (NYSE MKT:RNN): Rexahn Identifies RX-3117 Biomarker Presents Data at the 2015 AACR Annual Meeting Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today presents preclinical data on … Corey Williams, April 20, 2015
Biotech StocksNew Coverage MLV Pounds the Table on Rexahn Pharmaceuticals In a research report released today, MLV analyst Vernon Bernardino initiated coverage on shares of Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) with a Buy rating and … Ben Mahaney, Editor, March 20, 2015
Biotech StocksInsights Roth Capital Maintains Buy On Rexahn Pharmaceuticals Following 3Q14 Results Roth Capital analyst Joseph Pantginis maintained a Buy rating on Rexahn Pharmaceuticals (NYSE:RNN) with a $3 price target, following the company’s third-quarter results, posting EPS … Ben Mahaney, Editor, November 13, 2014
Biotech StocksInsights Roth Capital Maintained Buy On Rexahn Pharmaceuticals On FDA Orphan Designation In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Rexahn Pharmaceuticals (NYSE:RNN) with a $3 price target, … Ben Mahaney, Editor, September 25, 2014
Biotech StocksInsights Rexahn Represents An Attractive Investment Opportunity, Says Roth Capital In a research report released July 18, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Rexahn Pharmaceuticals (RNN) with a $3 price target, … Editor Ben Weinberg, July 21, 2014
